Drug intelligence / Profile preview

D5-2243

Development stage: Unknown
Lead developer: Zymeworks
Modality: Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

D5-2243 is a bispecific T-cell engager designed to target HLA-A*02/NY-ESO, an antigen commonly expressed in various advanced solid tumors. The drug functions by redirecting T cells to recognize and kill tumor cells expressing the NY-ESO antigen in the context of HLA-A*02. It is being evaluated as an immunotherapy for patients with advanced solid tumors and represents a novel approach within the field of targeted cancer immunotherapies[1].

Targets

CD3 (T-cell surface glycoprotein CD3)HLA class I histocompatibility antigen, A-2 alpha chain/Cancer-testis antigen 1B peptide-MHC complex

Beyond the preview

Go deeper on D5-2243.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D5-2243.

Explore the full profile